000288782 001__ 288782
000288782 005__ 20250129093114.0
000288782 0247_ $$2doi$$a10.1093/ejendo/lvae015
000288782 0247_ $$2pmid$$apmid:38436478
000288782 0247_ $$2ISSN$$a0001-5598
000288782 0247_ $$2ISSN$$a0804-4643
000288782 0247_ $$2ISSN$$a1479-683X
000288782 0247_ $$2ISSN$$a2053-4167
000288782 0247_ $$2altmetric$$aaltmetric:160337064
000288782 037__ $$aDKFZ-2024-00465
000288782 041__ $$aEnglish
000288782 082__ $$a610
000288782 1001_ $$aZitrick, František$$b0
000288782 245__ $$aMajor Improvement in Thyroid Cancer Survival of Elderly Patients in the Nordic Countries.
000288782 260__ $$aOxford$$bOxford University Press$$c2024
000288782 3367_ $$2DRIVER$$aarticle
000288782 3367_ $$2DataCite$$aOutput Types/Journal article
000288782 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1738139448_5571
000288782 3367_ $$2BibTeX$$aARTICLE
000288782 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000288782 3367_ $$00$$2EndNote$$aJournal Article
000288782 500__ $$a#LA:Z999# / 2024 Mar 2;190(3):K32-K36
000288782 520__ $$aWe describe age-specific survival in thyroid cancer (TC) from Denmark, Finland, Norway and Sweden over a 50-year period.Population-based survival study.Relative 5-year survival data were obtained from the NORDCAN database for years 1972- 2021.In the first period 1972-76, 5-year survival in TC in Finland, Norway and Sweden was 90% or higher but a strong negative step-wise age gradient was observed which was worse for men than women. Over time survival increased and in the final period, 2017-21, survival for all women and Danish men up to age 69 years was about 90% or higher, and for men from the other countries only marginally lower. Even for older women survival reached 80%, for older men somewhat less.Age disadvantage in TC survival was for most part corrected over the 50 year period and the remaining task is to boost survival for the oldest patients.
000288782 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000288782 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000288782 650_7 $$2Other$$aanaplastic cancer
000288782 650_7 $$2Other$$ametastasis
000288782 650_7 $$2Other$$aprognosis
000288782 650_7 $$2Other$$arelative survival
000288782 650_7 $$2Other$$atrends
000288782 7001_ $$aKoskinen, Anni$$b1
000288782 7001_ $$aLiska, Vaclav$$b2
000288782 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b3$$udkfz
000288782 7001_ $$00000-0001-7103-8530$$aHemminki, Akseli$$b4
000288782 7001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b5$$eLast author$$udkfz
000288782 773__ $$0PERI:(DE-600)1485160-X$$a10.1093/ejendo/lvae015$$gp. lvae015$$n3$$pK32-K36$$tEuropean journal of endocrinology$$v190$$x0001-5598$$y2024
000288782 909CO $$ooai:inrepo02.dkfz.de:288782$$pVDB
000288782 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000288782 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000288782 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000288782 9141_ $$y2024
000288782 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000288782 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000288782 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000288782 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000288782 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000288782 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000288782 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000288782 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000288782 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-21
000288782 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J ENDOCRINOL : 2022$$d2023-10-21
000288782 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000288782 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000288782 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000288782 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J ENDOCRINOL : 2022$$d2023-10-21
000288782 9202_ $$0I:(DE-He78)Z999-20160331$$kZ999$$lErimitus im DKFZ$$x0
000288782 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000288782 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000288782 9201_ $$0I:(DE-He78)Z999-20160331$$kZ999$$lErimitus im DKFZ$$x2
000288782 980__ $$ajournal
000288782 980__ $$aVDB
000288782 980__ $$aI:(DE-He78)B062-20160331
000288782 980__ $$aI:(DE-He78)HD01-20160331
000288782 980__ $$aI:(DE-He78)Z999-20160331
000288782 980__ $$aUNRESTRICTED